These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22075605)

  • 1. Clinical significance of serum levels of secretory leukocyte protease inhibitor in patients with systemic sclerosis.
    Aozasa N; Asano Y; Akamata K; Noda S; Masui Y; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
    Mod Rheumatol; 2012 Aug; 22(4):576-83. PubMed ID: 22075605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
    Kodera M; Hasegawa M; Komura K; Yanaba K; Takehara K; Sato S
    Arthritis Rheum; 2005 Sep; 52(9):2889-96. PubMed ID: 16142750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum alarm antiproteases in systemic sclerosis patients.
    Olewicz-Gawlik A; Trzybulska D; Graniczna K; Kuznar-Kaminska B; Katulska K; Batura-Gabryel H; Frydrychowicz M; Danczak-Pazdrowska A; Mozer-Lisewska I
    Hum Immunol; 2017 Sep; 78(9):559-564. PubMed ID: 28606626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum concentrations of triggering receptor expressed on myeloid cells-1 in diffuse cutaneous systemic sclerosis: association with severity of pulmonary fibrosis.
    Tomita H; Ogawa F; Hara T; Yanaba K; Iwata Y; Muroi E; Yoshizaki A; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2010 Apr; 37(4):787-91. PubMed ID: 20156945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity.
    Yanaba K; Asano Y; Tada Y; Sugaya M; Kadono T; Sato S
    Mod Rheumatol; 2012 Sep; 22(5):668-75. PubMed ID: 22160844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
    Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease.
    Rizzi M; Sarzi-Puttini P; Airoldi A; Antivalle M; Battellino M; Atzeni F
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S142-7. PubMed ID: 26339893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of organ involvement in systemic sclerosis by serum biomarkers and peripheral endothelial function.
    Kawashiri SY; Nishino A; Igawa T; Takatani A; Shimizu T; Umeda M; Fukui S; Okada A; Suzuki T; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakashima M; Mizokami A; Matsuoka N; Migita K; Ogawa F; Ikeda S; Maemura K; Nakamura H; Origuchi T; Maeda T; Kawakami A
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):102-108. PubMed ID: 29652651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis.
    Olewicz-Gawlik A; Danczak-Pazdrowska A; Kuznar-Kaminska B; Gornowicz-Porowska J; Katulska K; Trzybulska D; Batura-Gabryel H; Silny W; Poplawski D; Hrycaj P
    Int J Rheum Dis; 2014 Jul; 17(6):664-70. PubMed ID: 24467649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased serum pentraxin 3 in patients with systemic sclerosis.
    Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum resistin levels: a possible correlation with pulmonary vascular involvement in patients with systemic sclerosis.
    Masui Y; Asano Y; Akamata K; Aozasa N; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Yanaba K; Tada Y; Sugaya M; Sato S; Kadono T
    Rheumatol Int; 2014 Aug; 34(8):1165-70. PubMed ID: 24141536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased production of soluble inducible costimulator in patients with diffuse cutaneous systemic sclerosis.
    Yanaba K; Asano Y; Noda S; Akamata K; Aozasa N; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Tada Y; Sugaya M; Kadono T; Sato S
    Arch Dermatol Res; 2013 Jan; 305(1):17-23. PubMed ID: 23053221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum omentin levels: A possible contribution to vascular involvement in patients with systemic sclerosis.
    Miura S; Asano Y; Saigusa R; Yamashita T; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Sato S; Kadono T
    J Dermatol; 2015 May; 42(5):461-6. PubMed ID: 25766303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.
    Grosicka A; Manasar A; Kucharz EJ; Kotyla PJ
    Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):541-549. PubMed ID: 31174823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.
    Launay D; Mouthon L; Hachulla E; Pagnoux C; de Groote P; Remy-Jardin M; Matran R; Lambert M; Queyrel V; Morell-Dubois S; Guillevin L; Hatron PY
    J Rheumatol; 2007 May; 34(5):1005-11. PubMed ID: 17444586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels, tissue expression and cellular secretion of macrophage migration inhibitory factor in limited and diffuse systemic sclerosis.
    Corallo C; Paulesu L; Cutolo M; Ietta F; Carotenuto C; Mannelli C; Romagnoli R; Nuti R; Giordano N
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S98-105. PubMed ID: 26005773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Asano Y; Ihn H; Yamane K; Yazawa N; Kubo M; Fujimoto M; Tamaki K
    Arthritis Rheum; 2001 Jun; 44(6):1363-9. PubMed ID: 11407696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
    Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free light chains of immunoglobulins in patients with systemic sclerosis: correlations with lung involvement and inflammatory milieu.
    Bosello S; Basile U; De Lorenzis E; Gulli F; Canestrari G; Napodano C; Parisi F; Pocino K; Di Mario C; Tolusso B; Ferraccioli G; Gremese E
    J Clin Pathol; 2018 Jul; 71(7):620-625. PubMed ID: 29447111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Surfactant proteins-A and D as important serum markers for interstitial lung disease in patients with polymyositis or dermatomyositis].
    Chen F; Shu XM; Wang DX; Xie Y; Wang GC
    Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(31):2182-5. PubMed ID: 23158422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.